- Home
- PHAR vs FLX Comparison
PHAR vs FLX Comparison
Compare PHAR & FLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- FLX
- Stock Information
- Founded
- PHAR 1988
- FLX 2013
- Country
- PHAR Netherlands
- FLX China
- Employees
- PHAR N/A
- FLX N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- FLX
- Sector
- PHAR Health Care
- FLX
- Exchange
- PHAR Nasdaq
- FLX NYSE
- Market Cap
- PHAR 718.1M
- FLX N/A
- IPO Year
- PHAR N/A
- FLX 2024
- Fundamental
- Price
- PHAR $10.27
- FLX $3.27
- Analyst Decision
- PHAR Strong Buy
- FLX
- Analyst Count
- PHAR 3
- FLX 0
- Target Price
- PHAR $30.00
- FLX N/A
- AVG Volume (30 Days)
- PHAR 4.3K
- FLX 96.0K
- Earning Date
- PHAR 07-31-2025
- FLX 08-27-2025
- Dividend Yield
- PHAR N/A
- FLX N/A
- EPS Growth
- PHAR N/A
- FLX N/A
- EPS
- PHAR N/A
- FLX N/A
- Revenue
- PHAR $320,708,000.00
- FLX $595,490,250.00
- Revenue This Year
- PHAR $13.31
- FLX N/A
- Revenue Next Year
- PHAR $7.68
- FLX N/A
- P/E Ratio
- PHAR N/A
- FLX N/A
- Revenue Growth
- PHAR 24.13
- FLX N/A
- 52 Week Low
- PHAR $6.65
- FLX $2.01
- 52 Week High
- PHAR $12.61
- FLX $21.95
- Technical
- Relative Strength Index (RSI)
- PHAR 48.21
- FLX N/A
- Support Level
- PHAR $10.46
- FLX N/A
- Resistance Level
- PHAR $11.49
- FLX N/A
- Average True Range (ATR)
- PHAR 0.37
- FLX 0.00
- MACD
- PHAR -0.12
- FLX 0.00
- Stochastic Oscillator
- PHAR 27.62
- FLX 0.00
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.